MaxCyte, Inc. (AIM:MXCT)
236.80
-3.20 (-1.33%)
Mar 26, 2025, 9:27 AM GMT+1
MaxCyte Employees
MaxCyte had 114 employees as of December 31, 2024. The number of employees decreased by 29 or -20.28% compared to the previous year.
Employees
114
Change (1Y)
-29
Growth (1Y)
-20.28%
Revenue / Employee
270.65K GBP
Profits / Employee
-287.66K GBP
Market Cap
254.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 25,408 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,988 |
Genus | 3,500 |
MaxCyte News
- 10 days ago - MaxCyte: Strong Revenues, Fast-Growing Cell-Therapy Market, Very Low Share Price - Seeking Alpha
- 14 days ago - MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges - GuruFocus
- 14 days ago - Q4 2024 MaxCyte Inc Earnings Call Transcript - GuruFocus
- 14 days ago - MaxCyte, Inc. (MXCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - MaxCyte GAAP EPS of -$0.10 beats by $0.03, revenue of $8.7M beats by $0.79M - Seeking Alpha
- 14 days ago - MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance - GlobeNewsWire
- 6 weeks ago - MaxCyte, TG Therapeutics sign strategic platform license to advance autoimmune cell therapeutics programs - Seeking Alpha
- 6 weeks ago - MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs - GlobeNewsWire